PMS of Trazenta on the Long-term Use as Add-on Therapy

Boehringer Ingelheim

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Trazenta

Study type: Observational

Funder types: Industry

Identifiers

NCT01904383

1218.147

Details and patient eligibility

About

Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as add-on therapy in patients with type 2 diabetes mellitus.

Enrollment: 4,057 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients with type 2 diabetes mellitus who are treated with anti-diabetic drugs and have never been treated with Trazenta® Tablets (linagliptin) before enrollment will be included.

Exclusion criteria

None

Trial design

4,057 participants in 1 patient group

Trazenta

Treatment:

Drug: Trazenta